|
|
|
|
| LEADER |
04942nam a2200493 4500 |
| 001 |
on1023575294 |
| 003 |
OCoLC |
| 005 |
20200326101151.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
180219s2018 mau ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d EBLCP
|d DKU
|d OCLCF
|d NLE
|d UAB
|d YDX
|d UPM
|d OCLCQ
|d D6H
|d INT
|d YDX
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 1023737070
|
| 020 |
|
|
|a 9780128143438
|q (electronic book)
|
| 020 |
|
|
|a 0128143436
|q (electronic book)
|
| 020 |
|
|
|a 9780128143421
|
| 020 |
|
|
|a 0128143428
|
| 035 |
|
|
|a (OCoLC)1023575294
|z (OCoLC)1023737070
|
| 050 |
|
4 |
|a QD431.A3
|b P76 2018
|
| 072 |
|
7 |
|a SCI
|x 013040
|2 bisacsh
|
| 082 |
0 |
4 |
|a 547.7
|2 23
|
| 245 |
0 |
0 |
|a Protein-protein interactions in human disease.
|p Part B /
|c edited by Rossen Donev.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2018.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v volume 111
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
|
|a Front Cover; Protein-Protein Interactions in Human Disease, Part B; Copyright; Contents; Contributors; Preface; Chapter One: Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design; 1. Introduction; 2. Methods to Study PPIs and Their Inhibition; 2.1. Coimmunoprecipitation; 2.2. Pull-Down Assay; 2.3. Proximity Ligation Assay; 2.4. Enzyme Fragment Complementation Assay (PathHunter Assay); 2.5. Surface Plasmon Resonance; 2.6. Mutational Studies to Identify Hot Spots in PPI; 3. Inhibition of Dimerization of Protein and PPI.
|
| 505 |
8 |
|
|a 4. Design of Compounds Based on Protein Interface4.1. Structure-Based Drug Design; 4.2. Fragment-Based Discovery in PPI Inhibition; 4.3. High-Throughput Screening; 5. Homodimers; 5.1. G-Protein-Coupled Receptors; 5.2. Receptor Tyrosine Kinase-Like Orphan Receptor 2; 5.3. Glucocorticoid Receptor; 5.4. Amyloid Precursor Protein Dimers; 5.5. EGFR Homodimers; 6. Heterodimerization of Proteins and Inhibition; 6.1. p45-p75 Heterodimers; 6.2. IL-6-IL-6Rα; 6.3. Epidermal Growth Factor Receptors; 6.3.1. Structure of ECDs of Proteins; 6.3.2. Design Concept; 6.4. PD-1-PD-L1 Pathway; 6.5. CD-28/CD-80.
|
| 505 |
8 |
|
|a 6.6. CD2-CD58 Interactions and the Design of Multicyclic Peptides6.6.1. Multicyclic Peptide Approach; References; Chapter Two: Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old; 1. Introduction; 2. PPIs in Transmembrane Signaling; 2.1. Intramembrane and Cytoplasmic Interactions; 2.1.1. Single-Chain Receptors; 2.1.2. Multichain Receptors; 2.2. Transmembrane Signaling and Viral Evasion Strategies: Evolutionary and Molecular Aspects; 3. Intramembrane PPIs as a Therapeutic Target; 3.1. Cancer; 3.1.1. Nonsmall Cell Lung Cancer.
|
| 505 |
8 |
|
|a 3.1.2. Pancreatic Cancer3.2. Autoimmune Diseases; 3.2.1. Targeting T Cell Receptor; 3.2.2. Targeting TREM-1; 3.3. Sepsis; 3.4. Thrombosis; 3.5. Retinopathy; 4. Conclusions; Acknowledgments; References; Further Reading; Chapter Three: Targeting the Architecture of Deregulated Protein Complexes in Cancer; 1. Introduction; 2. RAS:RAF Signalosome and Network; 2.1. Background; 2.2. Small G Proteins of the RAS Family and RAF Family Serine-Threonine Kinases; 2.3. Physiological and Pathophysiological Functions; 2.4. Pharmacological Targeting of RAS:RAF Complexes; 3. PKA Signalosome and Network.
|
| 505 |
8 |
|
|a 3.1. Background3.2. Macromolecular PKA Complexes; 3.3. Pathological PKA Functions; 3.4. Pharmacological Targeting of PKA Emanating PPIs; 4. MYC:MAX Signalosome and Network; 4.1. The MYC:MAX Network; 4.2. Physiological and Oncogenic Functions; 4.3. Pharmacological Interference; 5. Conclusions; Acknowledgments; References; Chapter Four: Multifaceted Nucleolin Protein and Its Molecular Partners in Oncogenesis; 1. Introduction; 2. Structure of Nucleolin; 3. Role of Nucleolin in Ribosome Biogenesis and Gene Expression in Cancer Cells; 4. Functions of Nucleolin in DNA Repair and Genome Stability.
|
| 588 |
0 |
|
|a Online resource; title from digital title page (viewed on September 28, 2018).
|
| 650 |
|
0 |
|a Protein-protein interactions.
|
| 650 |
|
7 |
|a SCIENCE
|x Chemistry
|x Organic.
|2 bisacsh
|
| 650 |
|
7 |
|a Protein-protein interactions.
|2 fast
|0 (OCoLC)fst01079705
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Protein-protein interactions in human disease. Part B.
|b First edition.
|d London, United Kingdom : Academic Press, an imprint of Elsevier, 2018
|z 9780128143421
|z 0128143428
|w (OCoLC)1002834516
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 111.
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/bookseries/18761623/111
|z Full Text via HEAL-Link
|
